SCHEMBL1930484

SCHEMBL1930484

CC1C2CCC(C2)C1CO

nearest known ligand 0.31

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
GLB1 P16278 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14032358 1.00 GLB1 (0.31) GLB1
SCHEMBL9921598 1.00 GLB1 (0.31) GLB1
SCHEMBL8491866 0.81
SCHEMBL9605762 0.80
SCHEMBL278784 0.80
SCHEMBL561105 0.80
SCHEMBL9606081 0.80
SCHEMBL11421394 0.80
SCHEMBL19860431 0.80
SCHEMBL1461040 0.80

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7507867-B2 Bicyclo[2.2.1] heptane derivative IDEMITSU KOSAN CO., LTD. (JP) 2009-03-24 US claimed
US-20060004123-A1 PHASE CHANGE INK PRINTING PROCESS XEROX CORPORATION 2006-01-05 US claimed
EP-0743574-B1 Migration imaging members XEROX CORP (US) 2000-12-27 EP claimed
EP-0743573-B1 Method for obtaining image contrast migration imaging members XEROX CORP (US) 2000-09-06 EP claimed
EP-0743574-A2 Migration imaging members XEROX CORPORATION (US) 1996-11-20 EP claimed
EP-0743573-A2 Method for obtaining image contrast migration imaging members XEROX CORPORATION (US) 1996-11-20 EP claimed
US-5563014-A SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT XEROX CORPORATION (US) 1996-10-08 US claimed
US-5514505-A SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE XEROX CORPORATION (US) 1996-05-07 US claimed
CN-111918953-B Lubricant base oil, lubricant composition containing the same, and continuously variable transmission using the same 出光兴产株式会社 2022-10-04 CN disclosed
EP-3778834-A1 LUBRICATING OIL BASE OIL, LUBRICATING OIL COMPOSITION CONTAINING SAME, AND CONTINUOUSLY VARIABLE TRANSMISSION USING SAID LUBRICATING OIL COMPOSITION Idemitsu Kosan Co.,Ltd. (JP) 2021-02-17 EP disclosed
US-20200339570-A1 BICYCLIC DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2020-10-29 US disclosed
US-10669268-B2 Bicyclic derivatives HOFFMANN-LA ROCHE INC. (US) 2020-06-02 US disclosed
EP-2900669-B1 HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AND RELATED COMPOUNDS AS AUTOTAXIN (ATX) INHIBITORS AND AS INHIBITORS OF THE LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION FOR TREATING E.G. RENAL DISEASES HOFFMANN LA ROCHE (CH) 2019-09-04 EP disclosed
EP-2597140-B1 USE OF A LUBRICATING OIL COMPOSITION FOR CONTINUOUSLY VARIABLE TRANSMISSION IDEMITSU KOSAN CO (JP) 2019-07-03 EP disclosed
EP-0402881-B1 Process for improving the coefficient of traction. IDEMITSU KOSAN COMPANY LIMITED (JP) 1993-09-29 EP disclosed
WO-1993004070-A1 SUBSTITUTED ACRYLAMIDO-PENICILLANIC ACID DERIVATIVES SMITHKLINE BEECHAM, PLC (GB) 1993-03-04 WO disclosed
EP-0508292-A1 Traction drive fluid, process for producing the same and bicyclo octane compound IDEMITSU KOSAN COMPANY LIMITED (JP) 1992-10-14 EP disclosed
US-5126065-A PROCESS FOR IMPROVING THE COEFFICIENT OF TRACTION AND TRACTION DRIVE FLUID IDEMITSU KOSAN CO., LTD. (JP) 1992-06-30 US disclosed
EP-0421752-A2 Substituted acrylamido-penicillanic acid derivatives Beecham Group p.l.c. (GB) 1991-04-10 EP disclosed
EP-0402881-A1 Process for improving the coefficient of traction. IDEMITSU KOSAN COMPANY LIMITED (JP) 1990-12-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10669268-B2 Bicyclic derivatives CCNY, BICRA, UQCRB GLB1 2066/4885
US-20200339570-A1 BICYCLIC DERIVATIVES CCNY, BICRA, UQCRB GLB1 2066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.